<DOC>
	<DOCNO>NCT00784888</DOCNO>
	<brief_summary>The purpose study follow safety quality life outcomes patient switch tamoxifen therapy aromatase inhibitor therapy .</brief_summary>
	<brief_title>Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy</brief_title>
	<detailed_description>Group patient use aromatase inhibitor</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Patients endocrine responsive early stage postmenopausal breast cancer . Patients receive tamoxifen 23 year adjuvant endocrine therapy . Patients approve switch aromatase inhibitor treatment patient recruitment period . Patients inform study accept participate . Patients psychological disorder prevent understanding questionnaire use evaluation quality life / patient illiterate .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>aromatase inhibitor</keyword>
	<keyword>quality life</keyword>
	<keyword>safety</keyword>
	<keyword>postmenopausal breast cancer</keyword>
</DOC>